US Drug Pricing Reform: No More Medicare 'Gravy Train,' Azar Tells Pharma
HHS secretary urges serious proposals from biopharma on enhancing price negotiation in Medicare Parts D and B, promising action from the Administration whether the industry cooperates or not.